 INDIANAPOLIS, Sept. 30, 2021 PRNewswire -- Eli Lilly and Company NYSE: LLY and Incyte NASDAQ: INCY announced today detailed results from two pivotal Phase 3 trials BRAVE-AA1 and BRAVE-AA2, which found once-daily OLUMIANT baricitinib 4-mg was superior to placebo in achieving significant scalp hair regrowth as early as 24 weeks in adults with severe alopecia areata AA as defined by 50 scalp hair loss at baseline. 